Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

BRIDGEWATER – Shares of Insmed, a pharmaceutical firm at the intersection of Route 202-206 and Allen Road, jumped 8% on the NASDAQ after the federal Food and Drug Administration approved the company's ...

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...

The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated’s (NASDAQ:INSM) Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

InsmedINSM stock hit a record high Tuesday after the Food and Drug Administration approved its drug, brensocatib, for ...

Brinsupri is the first approved therapy to address the underlying inflammatory process of non-cystic fibrosis bronchiectasis ...

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.